Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial Dermatology and Therapy February 2022;12(2):495-510
Date
02/01/2022
DOI
10.1007/s13555-021-00649-yScopus ID
2-s2.0-85123098014 (requires institutional sign-in at Scopus site)
28 CitationsAuthor List
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB
Author
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of Wisconsin